Viewing Study NCT06483334


Ignite Creation Date: 2025-12-25 @ 2:36 AM
Ignite Modification Date: 2025-12-28 @ 8:55 PM
Study NCT ID: NCT06483334
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-23
First Post: 2024-06-21
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module